精神分裂症患者的凝甲 (LY2140023):一个系统性审查和元分析
Hala Aboushawareb1, Omar F Abbas2, Hend Ghabour3
1Faculty of medicine, Mansoura university, Mansoura, Egypt. Halasalahh25@gmail.com.
BMC psychiatry
|August 8, 2025
概括
与安慰剂或抗精神病药物相比,Pomaglumetad methionil (LY2140023) 对精神分裂症没有显著的疗效. 虽然它在体重增加和益生菌素方面具有更好的副作用概况,但这并不能弥补其缺乏治疗益处.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
背景情况:
- 波马格卢梅塔德甲基尼尔 (LY2140023) 是一种选择性的甲基胺基因酸受体2/3的激动剂.
- 它提供了一种与传统抗精神病药物不同的新型作用机制,避免了直接的多巴胺或血清素受体相互作用.
- 这种独特的特征表明,与现有治疗相比,副作用的特征可能不同.
研究的目的:
- 系统地审查和元分析Pomaglumetad methionil的疗效.
- 为了比较其在精神分裂症治疗中与安慰剂和非典型抗精神病药物的有效性.
- 评估这一新型药物的整体治疗潜力.
主要方法:
- 一个全面的文献搜索确定了相关的随机临床试验 (RCT).
- 研究的质量是使用Cochrane风险偏差2 (ROB-2) 工具来评估的.
- 统计分析采用了审查经理 (RevMan),计算了平均差异 (MD) 与95%信心区间 (CI).
主要成果:
- 该审查包括4个RCT. 与安慰剂相比,Pomaglumetad methionil在PANSS得分中没有统计学上显著的差异 (p=0.31).
- 它在降低PANSS分数方面不如非典型抗精神病药物有效 (p<0.00001).
- 然而,与非典型抗精神病药物相比,格甲基尼尔对体重增加 (p<0.00001) 和益生素水平 (p<0.0001) 产生显著影响.
结论:
- 在治疗精神分裂症方面,Pomaglumetad methionil (LY2140023) 缺乏一致的疗效.
- 尽管体重增加和益乳素升高的情况更为有利,但这些好处并不能弥补其治疗局限性.
- 药物的新机制并未转化为该患者群体的临床有效性.
相关概念视频
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
957
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
957
Drug Therapy
98
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
98
Psychosis and Antipsychotic Drugs: Overview
455
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
455
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Mania and Antimanic Drugs: Overview
320
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
320
Biological Causes of Schizophrenia
149
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
149


